Picture EBD Group World of Partnering Opportunities 650x100px

Financing › Details

AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech

	Period	2023-10-01
	Predecessor	AexeRNA Therapeutics–Linden Lake Venture Capital: investment, 202010 co-founding investor Linden Lake Venture Capital
	Money taker	AexeRNA Therapeutics Inc.
	Today	BioNTech (Group)
	Group	BioNTech (Group)
	Money source	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Product	aexLNP system
	Product 2	RNA technology
	Person	Haag, Thomas A. (Linden Lake Venture Capital + AexeRNA Therapeutics 202311 CEO + Co-Founder)
	Source	Bayer, Max [Fierce Biotech]. (11/6/23). "News: BioNTech Adds Bispecific Candidate, mRNA Delivery Startup as Cancer Work Takes Center Stage".

Record changed: 2024-01-09

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for BioNTech (Group)

[1] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
[2] BioNTech SE. (2/8/24). "Press Release: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs". Mainz & London....
[3] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
[4] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....
[5] WuXi Biologics. (1/11/24). "Press Release: WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates". Shanghai....
[6] BioNTech SE. (1/9/24). "Press Release: BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference". Mainz....
[7] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
[8] Biotheus Inc.. (11/6/23). "Press Release: Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications". Zhuhai....
[9] Bayer, Max [Fierce Biotech]. (11/6/23). "News: BioNTech Adds Bispecific Candidate, mRNA Delivery Startup as Cancer Work Takes Center Stage"....
[10] BioNTech SE. (10/31/23). "Press Release: BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting". Mainz....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]